Status:
UNKNOWN
Icotinib as Consolidation Therapy After Chemoradiotherapy in EGFR-Mutant Stage IIIA-IIIB Non-small Cell Lung Cancer
Lead Sponsor:
Betta Pharmaceuticals Co., Ltd.
Conditions:
EGFR Gene Mutation
Non Small Cell Lung Cancer Stage IIIA
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
The main purpose of this study is to evaluate the relapse free survival of patients who have EGFR-mutant stage IIIA-IIIB Non-small Cell Lung Cancer and receive Icotinib as consolidation therapy after ...
Detailed Description
This is a single center, single arm, open label and prospective clinical study. Patients who have EGFR-mutant stage IIIA-IIIB and unresectable lung adenocarcinoma will receive Icotinib as consolidatio...
Eligibility Criteria
Inclusion
- Unresectable stage IIIA-IIIB Non-small Cell Lung Cancer, histology or cytology confirmed lung adenocarcinoma, pathological specimens with EGFR 19 del and/or 21 L858R gene mutation detected by amplification refractory mutation system method
- Before receiving synchronous or sequential chemoradiotherapy, no metastasis detected by head MRI, bone scan, chest enhanced CT scan and the abdominal (including dual adrenal) enhanced CT scan
- Only received synchronous or sequential chemoradiotherapy as anti-tumor treatment; after that, chest enhanced CT showed no progressive disease (including Complete Response, Partial Response and Stable Disease )
- Platinum-based chemotherapy regimen, including: vinorelbine, docetaxel, paclitaxel, pemetrexed, etoposide, etc and combination of platinum (including but not limited to cisplatin and carboplatin)
- 3DCRT or IMRT radiotherapy technology with a dose of 95% PTV 60-66gy, 2Gy once daily, 5 times weekly, up to 30-33 times
- ECOG score 0-1
- Able to enter the group within 4-12 weeks after the completion of synchronous or sequential chemoradiotherapy
- Expected survival more than 12 weeks
Exclusion
- Other malignant tumors within five years, except for completely cured cervical carcinoma, basal or squamous cell carcinoma
- In addition to synchronous or sequential chemoradiotherapy, ever received other systemic anti-tumor treatment, including chemotherapy or targeted therapy
- Any unstable systemic disease, including active infection, uncontrolled hypertension, unstable angina, congestive heart failure, liver, kidney or metabolic disease
- Upper vena cava syndrome at baseline
- Idiopathic pulmonary fibrosis detected by CT at baseline
- Definite neurological or psychiatric disorders, including epilepsy or dementia
- Pregnant or lactating women
Key Trial Info
Start Date :
May 9 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 1 2023
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT03396185
Start Date
May 9 2018
End Date
February 1 2023
Last Update
July 18 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cancer Hospital, Chinese Academy of Medical Science
Beijing, China